Player FM - Internet Radio Done Right
21 subscribers
Checked 3h ago
Adăugat four ani în urmă
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !
Treceți offline cu aplicația Player FM !
Just the Facts: Ora Banda Mining achieves first ore at Sand King Underground Mine
Manage episode 456258735 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Ora Banda Mining Ltd (ASX:OBM). The company has intersected its first ore at the Sand King Underground Mine, part of the Davyhurst Gold Project in Western Australia and its ‘DRIVE to 150 Project’. Multiple ore lodes were intersected in the first crosscut at the 315 Level, just four months after establishing the portal, aligning with internal schedules. Development progress since late August includes 427 metres of decline and 835 metres of total excavation, completed on schedule and within budget, per the Final Investment Decision (FID). Initial capital works are finished, with the primary fan installation planned for January 2025. First stoping ore remains on track for Q1 2025, with steady-state production of 60,000 ounces expected by Q2 2025. Grade control drilling has confirmed high-grade gold, with results such as 9.5 g/t and 13.2 g/t. A recent surface exploration program at Sand King North has extended known mineralised zones, identifying grades of up to 31.3 g/t gold. The company projects combined output from Riverina and Sand King of 140,000–160,000 ounces by FY26. Ora Banda Mining anticipates strong growth in production and cashflows, with Sand King is considered key to its long-term strategy. #ProactiveInvestors #OraBandaMining #ASX #GoldMining, #SandKingMine, #DavyhurstProject, #UndergroundMining, #MiningNews, #AustralianMining, #GradeControl, #HighGradeGold, #GoldExploration, #ResourceExpansion, #ProductionMilestone, #MineDevelopment, #DRIVEto150, #MiningUpdates, #GoldOre, #WesternAustralia, #FinancialGrowth, #GoldProjects, #MiningFuture
…
continue reading
607 episoade
Manage episode 456258735 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Ora Banda Mining Ltd (ASX:OBM). The company has intersected its first ore at the Sand King Underground Mine, part of the Davyhurst Gold Project in Western Australia and its ‘DRIVE to 150 Project’. Multiple ore lodes were intersected in the first crosscut at the 315 Level, just four months after establishing the portal, aligning with internal schedules. Development progress since late August includes 427 metres of decline and 835 metres of total excavation, completed on schedule and within budget, per the Final Investment Decision (FID). Initial capital works are finished, with the primary fan installation planned for January 2025. First stoping ore remains on track for Q1 2025, with steady-state production of 60,000 ounces expected by Q2 2025. Grade control drilling has confirmed high-grade gold, with results such as 9.5 g/t and 13.2 g/t. A recent surface exploration program at Sand King North has extended known mineralised zones, identifying grades of up to 31.3 g/t gold. The company projects combined output from Riverina and Sand King of 140,000–160,000 ounces by FY26. Ora Banda Mining anticipates strong growth in production and cashflows, with Sand King is considered key to its long-term strategy. #ProactiveInvestors #OraBandaMining #ASX #GoldMining, #SandKingMine, #DavyhurstProject, #UndergroundMining, #MiningNews, #AustralianMining, #GradeControl, #HighGradeGold, #GoldExploration, #ResourceExpansion, #ProductionMilestone, #MineDevelopment, #DRIVEto150, #MiningUpdates, #GoldOre, #WesternAustralia, #FinancialGrowth, #GoldProjects, #MiningFuture
…
continue reading
607 episoade
Toate episoadele
×Livium Ltd (ASX:LIT, OTC:LMMFF) managing director and CEO Simon Linge talks with Proactive’s Tylah Tully about the company’s latest updates, focusing on its strategic initiatives and near-term goals. Linge highlighted Livium’s strong emphasis on scaling its battery recycling business to meet the growing influx of large-format lithium-ion batteries, positioning the company as a key player in this growing sector. He discussed two other patented technologies, including LieNA® technology, developed in partnership with Mineral Resources, which is moving to its next phase of development. Additionally, Livium’s battery materials technology has made progress with customer agreements and product portfolio advancements, enabling the company to scale this segment. Linge explained how the organisation was actively pursuing funding opportunities through strategic, public and private partnerships. On restructuring, Linge outlined the ongoing cost-saving measures and workforce changes designed to position Livium for sustainable growth through 2026. He emphasised the company’s commitment to securing battery recycling agreements and a pipeline for large-format battery supplies, which are expected to reach 25,000 tonnes by the end of the decade. Stay tuned for further updates on Livium’s recycling milestones, restructuring developments, and commercialisation efforts. #ProactiveInvestors #LiviumLtd #ASX #OTC #BatteryRecycling #LithiumIonBatteries #EnergyStorage #SustainableTechnology #ASXLIT #BatteryMaterials #CircularEconomy #SimonLinge…
P
Proactive - Interviews for investors
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Leeuwin Metals Ltd (ASX: LM1). Leeuwin Metals has raised A$3.25 million through a two-tranche share placement priced at A$0.098 per share, reflecting an 18.3% discount to the last closing price. The placement attracted strong interest from institutional and sophisticated investors, with contributions of approximately A$250,000 from directors and management, subject to shareholder approval. The placement comprises two tranches: Tranche 1 raised approximately A$1.55 million, while Tranche 2 is expected to raise A$1.7 million, contingent on shareholder approval at an extraordinary general meeting scheduled for February 2025. The funds will support exploration and drilling activities across Leeuwin’s Australian and Canadian project portfolio, working capital and placement costs. A key focus is the Marda Gold Project in Western Australia, which Leeuwin is acquiring from Ramelius Resources. Announced in December 2024, the acquisition is anticipated to conclude in Q1 2025. Leeuwin's management highlighted the strategic significance of the Marda acquisition, located in a renowned goldfield, as a growth opportunity for shareholders. The funding positions the company to advance its exploration programs across its highly prospective assets. #ProactiveInvestors #LeeuwinMetals #GoldMining #CapitalRaising #MardaGoldProject #ASXUpdate #InstitutionalInvestors #SophisticatedInvestors #GoldExploration #WesternAustralia #CanadaMining #MineralResources #SharePlacement #RameliusResources #MineralExploration #MiningProjects #CorporateUpdate #ExplorationFunding #InvestmentOpportunities #GoldFields #ASXNews…
P
Proactive - Interviews for investors
1 Sona Nanotech's cancer treatment study published in peer-reviewed journal Frontiers in Immunology 6:25
Sona Nanotech CEO David Regan joined Steve Darling from Proactive to share the publication of groundbreaking findings from the company’s pre-clinical breast cancer and melanoma efficacy studies in the prestigious scientific journal Frontiers in Immunology. This comprehensive research highlights the transformative potential of Sona’s Targeted Hyperthermia Therapy (THT) and includes critical new follow-up data on its immune-activating properties. Sona’s proprietary technology employs patented, biocompatible gold nanorods (GNRs) to deliver precision, non-invasive hyperthermia therapy directly to cancer cells. This approach minimizes systemic toxicity, a common drawback of traditional cancer treatments. The study demonstrated that Sona’s THT induces cancer-specific cell death while triggering a robust immune response, marking a significant breakthrough in cancer immunotherapy. Notably, the research revealed that the immune response activated by Sona’s THT is effective against cancers that are typically resistant to modern immunotherapies. This novel immunity offers a critical advantage, paving the way for new treatment possibilities in cases where conventional methods fall short. #proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerResearch #GoldNanorods #TargetedTherapy #Biotechnology #CancerTreatment #HyperthermiaTherapy #Immunology #MedicalBreakthroughs #Nanotechnology…
P
Proactive - Interviews for investors
AOTI Inc (AIM:AOTI) CEO, president, and co-founder Dr Mike Griffiths talked with Proactive about the company’s efforts to revolutionise chronic wound care. AOTI is focused on treating conditions like diabetic foot ulcers with its unique home-based oxygen therapy, designed to promote durable healing. Griffiths highlighted the staggering $80 billion US diabetic foot ulcer care market and shared that AOTI is well-positioned to expand within this space. He noted that AOTI’s strong clinical evidence and ability to reduce hospitalisations and amputations resonate strongly with payers and healthcare providers. He also shared recent milestones, including the company’s expansion into six Medicaid states, its five-year renewal of the Veterans Affairs contract, and ongoing efforts to broaden its international presence. Griffiths announced the start of enrolments for the venous leg ulcer (VLU) clinical trial and discussed its significance in building high-quality evidence for AOTI's therapy. AOTI, headquartered in the US and listed on AIM, has grown by over 30% annually for five years and Griffiths expects this growth to continue as it enters new markets like skilled nursing and long-term care. “We believe we’re in a very exciting sector, with solutions that deliver long-term outcomes,” he shared. Visit Proactive’s YouTube channel for more videos, and don’t forget to like, subscribe, and enable notifications for updates! #AOTI #ChronicWoundCare #DiabeticFootUlcers #MedicalTechnology #HealthcareInnovation #OxygenTherapy #Medicaid #VeteransAffairs #ClinicalTrials #MedTechGrowth…
P
Proactive - Interviews for investors
hVIVO PLC CEO Yamin 'Mo' Khan talked with Proactive's Stephen Gunnion about the company's involvement in a world-first Phase 3 human challenge trial for a pertussis (whooping cough) vaccine candidate. The trial, in partnership with ILiAD Biotechnologies, is expected to start in the second half of this year. Khan highlighted the importance of this milestone for hVIVO, noting that it will be the company's largest challenge trial to date and its first bacterial challenge trial. The trial data aims to secure FDA marketing authorisation, marking a pivotal moment for the utility of human challenge trials in vaccine development. According to Khan, "The goal is to get a better vaccine to patients faster. Pertussis is a severe disease, particularly for infants, and there's an urgent need for new vaccines." He further explained that hVIVO's state-of-the-art Canary Wharf facility will play a critical role in supporting this trial, equipped with expanded laboratory capabilities for bacterial analysis. The trial comes as cases of pertussis are on the rise, increasing sixfold between 2023 and 2024. ILiAD Biotechnologies has also secured FDA fast-track status and an MHRA innovation passport for this vaccine candidate. Khan emphasised the partnership's goal of addressing this unmet medical need and delivering an effective vaccine to patients worldwide. Visit Proactive's YouTube channel for more videos, and don’t forget to like, subscribe, and enable notifications for future updates. #hVIVO #VaccineDevelopment #WhoopingCough #Pertussis #ClinicalTrials #FDAApproval #BiotechInnovation #Phase3Trial #HumanChallengeTrials #HealthcareResearch…
Fineqia International Inc CEO Bundeep Singh Rangar talked with Proactive's Stephen Gunnion about launching the world’s first exchange-traded product (ETP) that deploys digital assets in yield-bearing decentralized finance (DeFi). Rangar explained the product's unique value, providing access to DeFi yield through a transparent, regulated security listed on the Vienna Stock Exchange. The Fineqia FTSE Cardano Enhanced Yield ETN (AV:YADA) is based on the Cardano network, a top ten cryptocurrency valued at over $35 billion, and allows investors to participate in DeFi activities such as borrowing, lending, and validating transactions, which generate fees. Unlike traditional ETFs and ETNs, Fineqia's product reinvests 80% of these yields back to investors, making it a truly innovative approach. Rangar highlighted the importance of partnering with FTSE Russell, a subsidiary of the London Stock Exchange, to ensure robust pricing data for this groundbreaking product. He added, "This is an icebreaker for what we want to do in the industry... We’re about being innovative and different." This collaboration sets a milestone for the ETP industry by combining blockchain technology and traditional finance, giving fund managers and retail investors easy access to decentralized finance through a familiar financial instrument. Visit Proactive's YouTube channel for more videos like this one, and don’t forget to give the video a like, subscribe to the channel, and enable notifications for updates! #Fineqia #DeFi #CryptoETP #DecentralizedFinance #Cardano #DigitalAssets #ETN #CryptoInvesting #Blockchain #FTSERussell…
P
Proactive - Interviews for investors
GoviEx Uranium Inc (TSX-V:GXU, OTCQX:GVXXF) CEO Daniel Major discussed the just-released feasibility study for the Mutanga Uranium project in Zambia with Proactive's Stephen Gunnion. Major highlighted that the study outlines solid project economics, including a net present value (NPV) of $243.00 million and an internal rate of return (IRR) of 20.8% at a uranium price of $90.00 per pound. He described Mutanga as a straightforward open-pit project benefiting from local infrastructure and low technical risks. The company plans to produce 2.20 million pounds of uranium annually over a 12-year lifespan. Major emphasised the potential for resource expansion from nearby satellite deposits, which could further enhance the project’s value. Additionally, he outlined the global uranium market dynamics, noting a deficit in supply and growing demand driven by new reactors, life extensions for existing reactors, and advancements in small modular reactors (SMRs). Looking ahead, GoviEx is targeting project construction by 2028 and is actively seeking debt financing and offtake agreements to move forward. Major said, "We’re already sharing our feasibility study with utilities to ensure we meet their requirements." Watch the full interview to learn more about GoviEx’s strategy for meeting global uranium demand. Don’t forget to like the video, subscribe to Proactive’s YouTube channel, and enable notifications for future updates! #GoviExUranium #MutangaProject #UraniumMining #ZambiaResources #EnergyDemand #UraniumFeasibility #LowRiskMining #GlobalEnergy #NuclearEnergy #SmallModularReactors…
P
Proactive - Interviews for investors
1 ANGLE PLC says Nature Medicine journal highlights Parsortix's role in cancer breakthrough 11:25
11:25
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
11:25ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO Andrew Newland talked with Proactive's Stephen Gunnion about groundbreaking research using the Parsortix system. This system has enabled significant advancements in cancer research, including a recent study published in Nature Medicine that explores stopping the metastatic spread of cancer. Newland explained how Parsortix helps identify and analyse circulating tumour cell clusters, which are critical to cancer progression. He highlighted research led by Professor Nicola Aceto at the Cancer Metastasis Laboratory in Zurich, where they discovered that FDA-approved cardiac drugs could break these clusters into individual cells. In mice and breast cancer patients, this approach showed potential to halt cancer progression. The CEO emphasised Parsortix's central role in identifying patients and monitoring treatment efficacy, predicting global interest and demand for the system. He also discussed ANGLE's broader work with cancer drug developers, including collaborations with companies like AstraZeneca and Eisai, to unlock new approaches to managing cancer. Newland concluded with optimism, envisioning a future where cancer could become a manageable condition, similar to how HIV/AIDS is now controlled. Discover more about this transformative research and ANGLE PLC’s contributions. Like this video, subscribe to Proactive’s channel, and enable notifications for future updates!" #ANGLEPLC #Parsortix #CancerResearch #CancerBreakthrough #Oncology #Metastasis #CirculatingTumorCells #MedicalInnovation #NatureMedicine #CancerAwareness…
P
Proactive - Interviews for investors
Iofina PLC (AIM:IOF, OTC:IOFNF) CEO Dr Tom Becker talked with Proactive's Stephen Gunnion about the company's record achievements in 2024 and its ambitious growth plans for 2025. Becker detailed the production of over 630 metric tons of iodine last year, including a 13% year-over-year increase. He highlighted that the new IO#10 plant, which reached full capacity in late 2024, will contribute significantly to this year's output. The company is also making strides with IO#11, set to begin production in Q3 2025, and ongoing discussions for IO#12, signalling further expansion. Becker emphasised strong global iodine demand, with prices climbing above $70 per kilogram, benefiting Iofina's operations. Despite minor shipping delays pushing sales into 2025, Becker assured investors of continued growth and progress. He also celebrated the company's safety track record, with no lost-time accidents since 2021. Stay tuned for more updates on Iofina PLC and its plans for the future. Don’t forget to like the video, subscribe to Proactive’s YouTube channel, and enable notifications for future updates!" #Iofina #IodineProduction #ChemicalIndustry #BusinessGrowth #RecordProduction #IO10Plant #IO11Plant #GlobalDemand #ChemicalSafety #ProactiveInvestors…
P
Proactive - Interviews for investors
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive's Stephen Gunnion with an update on the company's pancreatic cancer trials. The company recently announced preliminary results from its ASCEND phase 2 trial at the ASCO Gastrointestinal Conference. According to Mazzo, data from the randomized, double-blind, placebo-controlled Cohort A group demonstrated promising trends in overall survival and efficacy. He highlighted that four complete responses were observed in the Certepetide group out of 63 patients—a stark contrast to zero in the standard care group. This is particularly significant when compared to other trials, such as NAPOLI-3, which had only one complete response in nearly 400 patients. Mazzo also discussed Cohort B, which investigates a double-dose regimen of Certepetide to explore pharmacodynamic improvements and optimize treatment efficacy. In addition, Lisata released preliminary data from its iLSTA trial, which examines combining Certepetide with immunotherapy (Durvalumab) and cytotoxics for pancreatic cancer. Mazzo emphasized increased T-cell tumor penetration and higher partial response rates in early data, suggesting potential for enhanced treatment outcomes. Catch the full interview to learn more about these breakthroughs. Visit Proactive’s YouTube channel for updates, like this video, subscribe, and enable notifications to stay informed. #LisataTherapeutics #PancreaticCancer #ClinicalTrials #ASCENDTrial #Certepetide #CancerResearch #Immunotherapy #PharmaNews #BiotechInnovations #ProactiveInvestors…
P
Proactive - Interviews for investors
1 ImmuPharma CEO Tim McCarthy shares latest developments with P140 platform, road ahead 12:35
12:35
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
12:35ImmuPharma PLC (AIM:IMM) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company’s recent groundbreaking developments in autoimmune disease treatment. He highlighted the progress made with their P140 platform, emphasising its potential to address multiple autoimmune diseases and transform patient care. McCarthy explained, “This is a breakthrough in a lot of different ways,” referencing recent preclinical findings that allow the identification and categorisation of autoimmune diseases, paving the way for personalised medicine. He also noted the significant interest in P140 from major pharmaceutical companies, underlining its potential to deliver effective treatment without adverse effects. Additionally, McCarthy shared updates from the JP Morgan and Biotech Showcase conferences, where these advancements were presented to key industry players. ImmuPharma’s focus in 2025 includes expanding its partnerships and delivering on its transformative pipeline. Stay tuned for more updates on ImmuPharma’s innovations in the biotech space. Visit Proactive’s YouTube channel for more videos, and don’t forget to like, subscribe, and turn on notifications for future content. #ImmuPharma #AutoimmuneDiseases #P140Platform #PersonalizedMedicine #Biotech #TimMcCarthy #PharmaceuticalInnovation #LupusTreatment #CIDP #HealthcareRevolution…
P
Proactive - Interviews for investors
1 Giyani Metals announces 'transformative' SEZ licence in Botwana for commerical managanese plant 4:24
Giyani Metals Corp (TSX-V:EMM, OTC:CATPF) CEO Charles FitzRoy joined Proactive's Stephen Gunnion with news that the company has secured a 50-year Special Economic Zone (SEZ) Investor License for its battery-grade manganese (HPMSM) commercial plant site to be built in Botswana. The award of the SEZ License designates Giyani’s Commercial Plant as a Single Factory Special Economic Zone. The Commercial Plant will be located adjacent to its K.Hill manganese mine site, near Kanye, Botswana. FitzRoy said securing the SEZ License for its Commercial Plant is a transformative step for Giyani, and an important milestone on its path to becoming a leading producer of battery-grade manganese, particularly as its Demo Plant nears first production.…
P
Proactive - Interviews for investors
HeLIX Exploration PLC (AIM:HEX) chairman David Minchin joined Proactive's Stephen Gunnion with news that the company has upgraded its helium reserves and economic estimates for the Rudyard Project, in Montanta, and raised around £5 million through an equity issuance. The proceeds are earmarked to support spending on a gas processing plant and to progress the Rudyard and Ingomar Dome projects. Minchin said the decision to move forward with an equity raise comes after a detailed review of the economic model and terms of available debt finance. Helix announced that consultant Aeon Petroleum Consultants Corp has calculated helium reserves of 355 million cubic feet in the northern dome of the Rudyard Project. Over a 12.5-year project lifespan, Aeon estimates potential net revenue of $115.2 million and sets an asset valuation an NPV8 valuation of $77.9 million, assuming a helium price of $500 per thousand cubic feet (Mcf).…
P
Proactive - Interviews for investors
Ariana Resources PLC (AIM:AAU) managing director Kerim Sener talked with Proactive's Stephen Gunnion about the company’s production results and ongoing projects. Ariana has exceeded production guidance for the eighth consecutive year at its Zenit mining operation in Turkey, delivering nearly 21,000 ounces of gold in 2024. Sener emphasised that the Kiziltepe processing plant continues to perform well despite its age, aided by additional ore from the Tavsan operation. The company reported gross revenue of $54.70 million, its second-highest ever, bolstered by strong gold and silver prices. Sener noted favourable market conditions, supported by central bank buying and commodity price trends, which he expects to continue into 2025. Sener also highlighted exploration progress in Zimbabwe, with new assay results being integrated into a forthcoming resource model for the Dokwe project. Meanwhile, drilling in Kosovo's Slivova gold project is helping Ariana complete its earn-in to 51% of the project, with further updates expected soon. Sener expressed optimism for 2025, stating, "At the moment, we're hitting all our guidance figures and continuing to do well across exploration and development." For more updates on Ariana Resources, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and enable notifications for the latest news. #ArianaResources #GoldMining #TurkeyMining #ZimbabweExploration #KosovoGold #GoldPrices #GoldRevenue #MiningUpdate #InvestorNews #ProactiveInterviews…
Greatland Gold PLC (AIM:GGP, OTC:GRLGF) CEO Shaun Day talked with Proactive's Stephen Gunnion about the company's strong production numbers for December following the completion of the Telfer and Havieron acquisition, consolidating ownership under Greatland. The company delivered 33,000 ounces of gold equivalent in just 27 days. Day emphasised the robust financial position of Greatland, with $145 million in cash and an undrawn debt facility of $75 million, providing over $220 million in liquidity to support its mine plans and life extensions at Telfer. "One of the positive variances to that due diligence is just the receptiveness and the culture at site to being part of Greatland," said Day. He outlined key upcoming milestones, including the release of the Telfer JORC resource in Q1, the ASX cross-listing in Q2, and the Havieron feasibility study expected in the second half of the year. With plans for ongoing updates, shareholders can look forward to consistent progress throughout the year. Visit Proactive’s YouTube channel for more videos. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future updates. #GreatlandGold #MiningIndustry #GoldProduction #TelferMine #HavieronProject #ASXListing #MiningNews #GoldInvesting #ShaunDay #ResourceDevelopment…
Bun venit la Player FM!
Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.